Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medtronic To Compare Endeavor To Boston Scientific’s Taxus In New Trial

This article was originally published in The Gray Sheet

Executive Summary

Medtronic's addition of a fourth clinical trial to support its Endeavor AVT-578-eluting coronary stent is unlikely to delay the PMA filing past the previously stated target of summer 2005, the company asserts

You may also be interested in...



Medtronic DES study

Firm announces the first patient implant was performed April 11 in its 1,548-patient, randomized trial to support the Endeavor ABT-578-eluting stent PMA. The study, named ENDEAVOR IV, will compare Endeavor head-to-head against Boston Scientific's Taxus paclitaxel-eluting stent by measuring target vessel failure at nine months as the primary endpoint and major adverse cardiac events at 30 days as a secondary endpoint (1"The Gray Sheet" Feb. 28, 2005, p. 19)...

Medtronic DES study

Firm announces the first patient implant was performed April 11 in its 1,548-patient, randomized trial to support the Endeavor ABT-578-eluting stent PMA. The study, named ENDEAVOR IV, will compare Endeavor head-to-head against Boston Scientific's Taxus paclitaxel-eluting stent by measuring target vessel failure at nine months as the primary endpoint and major adverse cardiac events at 30 days as a secondary endpoint (1"The Gray Sheet" Feb. 28, 2005, p. 19)...

Boston Scientific Taxus U.S. Market Share Recoups From 56% Low On Recall

Boston Scientific's average Taxus drug-eluting stent sales of $7.4 mil. a day in the U.S. for the week ended Aug. 27 represents a return to 70% market share after dipping to 56% in the wake of a July recall, the firm says

Related Content

UsernamePublicRestriction

Register

MT020770

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel